Changeflow GovPing Healthcare & Life Sciences Cyclic Sulfonamide RNR Inhibitors for Cancer Tr...
Routine Notice Added Final

Cyclic Sulfonamide RNR Inhibitors for Cancer Treatment

Favicon for changeflow.com USPTO Patent Applications - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The USPTO has published a new patent application, US20260085067A1, detailing cyclic sulfonamide RNR inhibitors for cancer treatment. The application was filed on September 12, 2023, by inventors Anthony B. Pinkerton, Jacques Mauger, and Yen Pham Hong Truong.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a publication of a patent application (US20260085067A1) filed with the USPTO. It describes compounds and methods for treating cancer using cyclic sulfonamide ribonucleotide reductase (RNR) inhibitors. The application was filed on September 12, 2023, and lists Anthony B. Pinkerton, Jacques Mauger, and Yen Pham Hong Truong as inventors.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on entities. However, it signals potential future intellectual property developments in cancer therapeutics. Companies involved in drug discovery and development, particularly in oncology, should be aware of this filing for competitive intelligence and potential licensing opportunities.

Archived snapshot

Mar 26, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF

Application US20260085067A1 Kind: A1 Mar 26, 2026

Inventors

Anthony B. PINKERTON, Jacques MAUGER, Yen Pham Hong TRUONG

Abstract

Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a cyclic sulfonamide RNR inhibitor disclosed herein.

CPC Classifications

C07D 417/06 A61K 31/5415 A61K 31/549 A61K 31/554 A61P 35/00 C07B 59/002 C07D 417/14 C07D 419/06 C07D 513/04 C07D 515/04

Filing Date

2023-09-12

Application No.

19110333

View original document →

Named provisions

Abstract Inventors CPC Classifications

Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
September 12th, 2023
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260085067A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Discovery Cancer Treatment
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Cancer Treatment Drug Discovery

Get alerts for this source

We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!